Thermo Fisher And University Of California Join Forces To Develop Cell-Based Therapies
The agreement will accelerate the development of cell-based therapies, where Thermo Fisher will build and run a development center
You may also be interested in...
Two $1bn+ alliances were penned in April. Vertex and Obsidian entered into an agreement surrounding the discovery of therapies that regulate gene editing for the treatment of serious diseases. Obsidian is eligible for up to $75m in up-front payments and research milestones and could get another $1.3bn in potential milestone payments across up to five potential programs. Artios signed a three-year global research collaboration with Novartis to discover and validate next-generation DNA damage response targets to enhance Novartis’ radioligand therapies. In the top April M&A by deal value, Thermo Fisher and publicly traded contract research organization PPD announced a definitive agreement under which Thermo Fisher will pay $47.50 per share (a 23% premium to the 10-day pre-announcement average) in cash for PPD, for a purchase price of $17.4bn plus the assumption of approximately $3.5bn of net debt. Financing reached $14.6bn in biopharma, $1.2bn in device, and $2.4bn in diagnostics.
Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.
A pilot study of the augmented reality system suggests it improves the precision of knee arthroplasty surgery.